TScan Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.27) Per Share, Wedbush Forecasts (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Wedbush dropped their Q1 2024 earnings per share (EPS) estimates for TScan Therapeutics in a research report issued to clients and investors on Wednesday, April 17th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.27) for the quarter, down from their previous forecast of ($0.26). Wedbush has a “Outperform” rating and a $10.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.03) per share. Wedbush also issued estimates for TScan Therapeutics’ Q2 2024 earnings at ($0.23) EPS, Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.98) EPS, FY2025 earnings at ($1.08) EPS, FY2026 earnings at ($1.13) EPS and FY2027 earnings at ($0.91) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 7th.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $6.82 on Friday. The company has a market capitalization of $326.54 million, a P/E ratio of -3.61 and a beta of 0.90. The business’s 50 day moving average is $7.06 and its two-hundred day moving average is $5.69. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.18. TScan Therapeutics has a 12-month low of $1.62 and a 12-month high of $9.00.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The company had revenue of $7.21 million for the quarter, compared to the consensus estimate of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%.

Hedge Funds Weigh In On TScan Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Stifel Financial Corp lifted its position in TScan Therapeutics by 3.0% during the fourth quarter. Stifel Financial Corp now owns 120,400 shares of the company’s stock worth $702,000 after buying an additional 3,500 shares in the last quarter. Pale Fire Capital SE lifted its position in TScan Therapeutics by 30.2% during the fourth quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock worth $126,000 after buying an additional 4,998 shares in the last quarter. Jane Street Group LLC purchased a new position in TScan Therapeutics during the second quarter worth approximately $32,000. State Street Corp increased its stake in TScan Therapeutics by 79.1% during the first quarter. State Street Corp now owns 24,000 shares of the company’s stock worth $50,000 after acquiring an additional 10,600 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in TScan Therapeutics during the first quarter worth $37,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.